Similarly, the better prognosis of the low-risk group as defined by concurrent genes was ascertained regardless of clinical HER2 status, which was not the case for intrinsic genes in subgroup analyses of HER2 overexpressing breast cancers (n = 95) and breast cancers with normal HER2 status (n = 245) (Figure S5A-S5B and S6A-S6B, respectively). The gene discussed is ERBB2; the disease is breast carcinoma.